Clinical Trials · NCT01664624
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 40
- Start date
- Jul 2012
- Locations
- 2 sites, United States
- Primary endpoint
- Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1